ArticleFrontiers in immunology2026

Cost-effectiveness of perioperative durvalumab plus FLOT for resectable gastric and gastroesophageal junction adenocarcinoma in the United States.

Jiahao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.